NeuroSense Therapeutics Ltd. (NRSN) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-0.65 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.55 vs est $-0.65 (beat +15.4%). Analyst accuracy: 82%.
NRSN Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to NeuroSense Therapeutics Ltd. in the past 3 months
EPS Estimates — NRSN
82%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual –$0.55
vs Est –$0.65
▲ 18.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — NRSN
Revenue Trend
Analysts expect stable revenue going forward.
